Challenges – How did the idea of Cibiltech come about?
Stephane Tholander – I was already an entrepreneur when I met Alexandre Loupy, nephrologist and transplant surgeon at Inserm-AP-HP-University of Paris. He had compiled a unique database in kidney transplantation and developed an algorithm that predicts the risk of rejection of a transplant at three, five or ten years.
How is it useful?
The waiting list for kidney transplants is growing every year: more than 17,000 French people were waiting on January 1, 2021, a figure up 27%, while there are only 4,000 transplants performed per year . In the list are the people whose graft did not survive. After ten years, 50% of patients return to dialysis. Our goal is to extend the life of the graft.
How? ‘Or’ What?
The algorithm made it possible to create two applications. The first is used for the development of new drugs. We are able to predict the impact of such or such immunosuppressive treatment on the patient, and on the probability of graft survival. This reduces the duration of clinical studies. Our clients are labs like Novartis or Sanofi. This activity represents about half of our turnover, of 3.5 million euros.
What is the second application?
Our algorithm helps hospital doctors to better anticipate the deterioration of the condition of patients and their graft, in order to administer more personalized treatments to them, earlier. After each biological or clinical analysis in town or at the hospital, our tool analyzes the results, and if the probability of survival of the graft drops drastically, we alert the hospital team so that they can investigate further. For this second application, we are still conducting clinical studies.
Which hospitals use it?
We are deployed in around a hundred hospitals: 70 in the United States with the exclusive distributor CareDx, where 10,000 patients have been followed, and around thirty in Europe, notably Necker in Paris, Fundació Puigvert in Barcelona or Leeds Teaching Hospitals NHS Trust in England. In France, 2,000 patients have been followed. Ultimately, our model is based on reimbursement by health insurance. We expect to be eligible within two years. We are already the first digital medical device to have CE marking since the rules changed.
Why are you looking for 15 million?
To conduct our clinical study on an international scale and deploy our solution in the majority of major European and American hospitals. We are aiming for 100 million in turnover by 2027.
What is your growth dream?
Become a global leader in digital health. But if France has relied heavily on artificial intelligence in health, there are still deployment issues. We need sustainable reimbursement models, a modern IT ecosystem in hospitals, and training health professionals in digital technology, and those working in digital health.
Read the latest entrepreneurs club Why Raise is stepping into aesthetic medicine with the Clinique des Champs-Elysées
We would like to give thanks to the writer of this short article for this amazing web content
Medtech: Cibiltech seeks 15 million to help transplant patients – Teller Report
Check out our social media profiles as well as other related pageshttps://www.ai-magazine.com/related-pages/